Novo Nordisk has launched its Levemir (insulin detemir [rDNA origin] injection) FlexTouch insulin delivery device in the US.
Levemir is a man-made long-acting insulin used to control high blood sugar in adults and children with diabetes mellitus. Levemir FlexTouch is a prefilled insulin pen containing 300 units of insulin detemir.
The insulin delivery device doses in one-unit increments ranging from 1-80 units and is compatible with both NovoFine and the latest NovoTwist needles.
The Levemir FlexTouch insulin delivery device features a push-button that does not extend at any set dose and allows insulin to be administered by pressing the low injection force button.
FlexTouch received approval from the US Food and Drug Administration in November 2013 and the European Medicines Agency’s approval in July 2011.
Novo Nordisk has launched the latest insulin delivery device in several countries, including the UK, Canada, Denmark, and Japan.
Novo Nordisk diabetes marketing senior vice president Camille Lee said that the company is committed to developing devices to help the more than 29 million people with diabetes in the US.
"Levemir FlexTouch was designed to address the needs of these individuals, providing patients and their health care professionals with a new tool to help improve the way they manage their diabetes," Lee added.